The Healthy Brain and Child Development National Consortium Administrative Core

项目摘要/摘要 怀孕期间阿片类药物的使用很普遍，并与怀孕个体的不良后果有关 和发育中的孩子，包括胎儿生长迟缓、早产、出生体重降低、先天缺陷、 增加新生儿保健，增加后来行为(例如焦虑、注意力不集中)、认知(例如， 记忆缺陷、语言习得延迟)和新陈代谢问题。尽管阿片类药物的使用与 不良的孕产妇、胎儿和儿童结局、产生这些后果的机制和潜在的 产前阿片类药物暴露对儿童健康和发育(如大脑和行为)的影响仍然存在 很大程度上是未被开发的。这种病因学知识的缺乏导致了治疗、预防和治疗的停滞 缓解努力使个人和家庭容易受到不良后果的影响。健康的人 大脑和儿童发展研究(HBCD)是一项关于早期儿童发展的25个站点的纵向前瞻性研究 在美国，这将评估广泛的生物学(例如，神经成像、遗传学、表观遗传学)、行为 (例如，认知和情绪调节)、经验(例如，创伤)、社会(例如，种族主义)和健康(例如， 中国~7500名具有全国代表性的孕妇及其子女的精神病理学因素 从怀孕到童年中期。HBCD研究的一个主要目标是增加对潜力的了解 产前接触物质的后果。它将被丰富用于怀孕期间的母体物质使用 (即约25%的样本将在怀孕期间使用阿片类药物、大麻、酒精和/或烟草)和 一个独特的机会，让我们了解与阿片类药物使用有关的不良后果 在怀孕期间出现。尽管HBCD将是关于早期大脑和儿童发育的最大的长期研究 在美国取得的成果，核心议定书不包括收集投放的生物检疫制剂。这 回应NIDA/ORWH特别行政区行政补充通知的行政补充 兴趣：修复倡议：孕期生物素收集(Not-DA-23-005)建议利用 通过扩大核心HBCD方案的生物样品收集以包括递送标本进行HBCD研究 (胎盘、脐带组织、脐带血)。送货样本将从HBCD研究参与者的样本中收集 涉及多达14个HBCD站点(包括2,000多名参与者)，这些站点已在 对这一说法的回应。这将为大型企业提供前所未有的资源生成机会 科学界全面评估调节这种联系的病理生理机制 孕期阿片类药物和多种物质的使用与新生儿、婴儿和/或产妇健康不良之间的关系 结果，并反过来为创新的预防战略提供参考。

PROJECT SUMMARY/ABSTRACT Opioid use during pregnancy is widespread and associated with adverse outcomes for the pregnant individual and the developing child, including reduced fetal growth, premature birth, lower birth weight, congenital defects, increased neonatal healthcare, and heightened risk for later behavioral (e.g., anxiety, inattention), cognitive (e.g., memory deficits, delayed language acquisition), and metabolic problems. Despite opioid use being linked to adverse maternal, fetal, and child outcomes, the mechanisms through which these arise and the potential consequences of prenatal opioid exposure for child health and development (e.g., brain and behavior) remain largely unexplored. This lack of etiologic knowledge has contributed to stagnant treatment, prevention, and mitigation efforts leaving individuals and families susceptible to reverberating adverse outcomes. The HEALthy Brain and Child Development (HBCD) Study is a 25-site longitudinal prospective study of early child development in the US that will assess a broad spectrum of biological (e.g., neuroimaging, genetics, epigenetics), behavioral (e.g., cognition and emotional regulation), experiential (e.g., trauma), social (e.g., racism), and health (e.g., psychopathology) factors among ~7,500 nationally-representative pregnant women and their children from pregnancy to mid-childhood. A major goal of the HBCD Study is to increase understanding of the potential consequences of prenatal substance exposures. It will be enriched for maternal substance use during pregnancy (i.e., ~25% of the sample will be using opioids, cannabis, alcohol, and/or tobacco during pregnancy) and offers a unique opportunity to inform our understanding of how the adverse consequences associated with opioid use during pregnancy arise. Although HBCD will be the largest long-term study of early brain and child development outcomes in the US, the core protocol does not include the collection of delivery biospecimens. This Administrative Supplement in response to the NIDA/ORWH Administrative Supplement Notice of Special Interest: HEAL Initiative: Biospecimen Collection in Pregnancy (NOT-DA-23-005) proposes to leverage the HBCD Study by expanding the biospecimen collection of the Core HBCD Protocol to include delivery specimens (placenta, cord tissue, cord blood). Delivery samples will be collected from a sample of HBCD Study participants across up to 14 HBCD sites (encompassing over 2,000 participants) who have submitted applications in response to this NOSI. This will provide an unprecedented resource generating opportunity for the larger scientific community to comprehensively evaluate pathophysiological mechanisms that mediate the connection between opioid and polysubstance use during pregnancy and adverse neonatal, infant, and/or maternal health outcomes and, in turn, inform innovative preventive strategies.